2,4-二氯己烷 | 86525-66-8

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 有机氯化物
• 中文名称: 2,4-二氯己烷
• 英文名称: 2,4-Dichlor-hexan
• 英文别名: 2,4-Dichlor-n-hexan；2,4-Dichloro-hexan；2,4-dichloro-hexane；2,4-Dichlorohexane
• CAS: 86525-66-8
• 化学式: C₆H₁₂Cl₂
• 分子量: 155.067
• InChiKey: LHEKJUGTNGWYIA-UHFFFAOYSA-N

物化性质

• 熔点：
  -48.02°C (estimate)
• 沸点：
  175.06°C (estimate)
• 密度：
  1.0805 (estimate)
• 保留指数：
  964;985

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  8
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

安全信息

• 海关编码：
  2903199000

反应信息

• 作为反应物：
  描述：

  2,4-二氯己烷 、 1,4-二甲基-1,2,3,4-四氢萘 生成 1,4,5,8-Tetramethyl-1,2,3,4,5,6,7,8-octahydro-anthracene
  参考文献：
  名称：

  Gelin,R.; Chantegrel,B., Bulletin de la Societe Chimique de France, 1971, p. 2527 - 2544

  摘要：

  DOI：
• 作为产物：
  描述：

  2-氯(正)己烷 在 磺酰氯 、 过氧化苯甲酰 作用下， 生成 2,5-二氯己烷 、 2,2-二氯己烷 、 1,5-二氯己烷 、 2,4-二氯己烷
  参考文献：
  名称：

  Horner,L.; Schlaefer,L., Justus Liebigs Annalen der Chemie, 1960, vol. 635, p. 31 - 45

  摘要：

  DOI：

文献信息

• Process for preparation of polymer
  申请人：NIPPON ZEON CO., LTD.

  公开号：EP0397081A2

  公开（公告）日：1990-11-14

  In a process of polymerizing at least one cationically polymerizable vinyl monomer using an initiator consisting of Lewis acid and organic compound having group represented by the formula (1) functional wherein R¹ represents hydrogen, an alkyl group or an aryl group, R² represents an alkyl or aryl group, and X represents halogen, an alkoxy group or an acyloxy group. a process for preparation of a polymer of the vinyl monomer which comprises the polymerization is carried out in the presence of amine.

  在使用由路易斯酸和有机化合物组成的引发剂聚合至少一种可阳离子聚合的乙烯基单体的工艺中，路易斯酸和有机化合物具有由式（1）表示的官能团 其中，R¹代表氢、烷基或芳基，R²代表烷基或芳基，X代表卤素、烷氧基或酰氧基，乙烯基单体聚合物的制备过程包括在胺存在下进行聚合。
• Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
  申请人：Ardelyx, Inc.

  公开号：US11318129B2

  公开（公告）日：2022-05-03

  The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders. The methods generally comprise administering to a mammal in need thereof a pharmaceutically effective amount of a compound, or a pharmaceutical composition comprising such a compound, that is designed to be substantially active in the gastrointestinal (GI) tract to inhibit NHE-mediated antiport of sodium ions and hydrogen ions therein. More particularly, the method comprises administering to a mammal in need thereof a pharmaceutically effective amount of a compound, or a pharmaceutical composition comprising such a compound, that inhibits NHE-3, -2 and/or -8 mediated antiport of sodium and/or hydrogen ions in the GI tract and is designed to be substantially impermeable to the layer of epithelial cells, or more specifically the epithelium of the GI tract. As a result of the compound being substantially impermeable, it is not absorbed and is thus essentially systemically non-bioavailable, so as to limit the exposure of other internal organs (e.g., liver, heart, brain, etc.) thereto. The present disclosure is still further directed to a method wherein a mammal is administered such a compound with a fluid-absorbing polymer, such that the combination acts as described above and further provides the ability to sequester fluid and/or salt present in the GI tract.

  本公开内容涉及用于治疗与体液潴留或盐负荷过重相关的疾病的化合物和方法，如心力衰竭（尤其是充血性心力衰竭）、慢性肾病、终末期肾病、肝病和过氧化物酶体增殖激活受体（PPAR）γ激动剂诱导的体液潴留。本公开还涉及治疗高血压的化合物和方法。本公开还涉及治疗胃肠道疾病的化合物和方法，包括治疗或减轻与胃肠道疾病相关的疼痛。这些方法一般包括向有需要的哺乳动物施用药学上有效量的化合物或包含这种化合物的药物组合物，这种化合物在胃肠道中基本具有活性，可抑制其中钠离子和氢离子的NHE介导的反转运。更具体地说，该方法包括向有需要的哺乳动物施用药学上有效量的化合物或包含该化合物的药物组合物，该化合物可抑制胃肠道中NHE-3、-2和/或-8介导的钠离子和/或氢离子的反转运，且设计成基本上不渗透上皮细胞层，或更具体地说不渗透胃肠道上皮细胞。由于该化合物基本上不渗透，因此不会被吸收，从而基本上不会被全身生物利用，从而限制了其他内脏器官（如肝脏、心脏、大脑等）对该化合物的接触。本公开内容还进一步涉及一种方法，在这种方法中，哺乳动物与吸液聚合物一起服用这种化合物，从而使这种组合起到如上所述的作用，并进一步提供封存存在于消化道中的液体和/或盐的能力。
• MOLECULES HAVING PESTICIDAL UTILITY, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES, RELATED THERETO
  申请人：Dow Agrosciences LLC

  公开号：EP3283459B1

  公开（公告）日：2019-05-22
• SURFACE TREATMENT BY PHOTOPOLYMERISATION TO OBTAIN BIOCIDAL PROPERTIES
  申请人：PERICHAUD Alain

  公开号：US20120202912A1

  公开（公告）日：2012-08-09

  The present invention relates to a process for surface treatment of a solid substrate in which photopolymerisation and covalent grafting are performed in situ on said substrate of a biocidal copolymer, wherein steps are taken in which: a) said solid substrate is put in contact with a formulation comprising: 1—at least one monomer comprising a biocidal group, 2—at least one copolymerisable compound with said biocidal monomer comprising a multifunctional monomer or oligomer mono- di- or selected amongst acrylate, epoxide or vinyl ether monomers or oligomers, 3—at least one photoprimer selected amongst radical and/or cationic photoprimers, and 4—at least one grafting agent on said substrate, and b) photocopolymerisation and covalent grafting of the copolymers obtained are carried into effect by subjecting said formulation in contact with said solid substrate to ultraviolet radiation.
• COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS
  申请人：Ardelyx, Inc.

  公开号：US20200268741A1

  公开（公告）日：2020-08-27

  The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders. The methods generally comprise administering to a mammal in need thereof a pharmaceutically effective amount of a compound, or a pharmaceutical composition comprising such a compound, that is designed to be substantially active in the gastrointestinal (GI) tract to inhibit NHE-mediated antiport of sodium ions and hydrogen ions therein. More particularly, the method comprises administering to a mammal in need thereof a pharmaceutically effective amount of a compound, or a pharmaceutical composition comprising such a compound, that inhibits NHE-3, -2 and/or -8 mediated antiport of sodium and/or hydrogen ions in the GI tract and is designed to be substantially impermeable to the layer of epithelial cells, or more specifically the epithelium of the GI tract. As a result of the compound being substantially impermeable, it is not absorbed and is thus essentially systemically non-bioavailable, so as to limit the exposure of other internal organs (e.g., liver, heart, brain, etc.) thereto. The present disclosure is still further directed to a method wherein a mammal is administered such a compound with a fluid-absorbing polymer, such that the combination acts as described above and further provides the ability to sequester fluid and/or salt present in the GI tract.

表征谱图